RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of RNXT
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

RenovoRx, Inc. stock price ended at $1.21 on Tuesday, after losing 0%.
(Updated on Apr 30, 2024)

Sell candidate since Apr 29, 2024 PDF

No changes to the price of RenovoRx, Inc. stock on the last trading day (Tuesday, 30th Apr 2024). During the last trading day the stock fluctuated 5.79% from a day low at $1.21 to a day high of $1.28. The price has risen in 5 of the last 10 days and is up by 7.11% over the past 2 weeks.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -23.78% during the next 3 months and, with a 90% probability hold a price between $0.80 and $1.12 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

RNXT Signals & Forecast

There are mixed signals in the stock today. The RenovoRx, Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $1.22 and $1.29. A break-up above any of these levels will issue buy signals. Volume fell on the last day without any changes to the price. This does not cause any direct divergence but may be an early warning and a possible "turning point". The very low volume increases the risk and reduces the other technical signals issued. A buy signal was issued from a pivot bottom point on Tuesday, April 16, 2024, and so far it has risen 7.11%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for RenovoRx, Inc. stock

RenovoRx, Inc. finds support from accumulated volume at $1.18 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day, but be aware of low or falling volume as this increases the risk. During the last day, the stock moved $0.0700 between high and low, or 5.79%. For the last week the stock has had daily average volatility of 6.97%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (RNXT) For The Upcoming Trading Day Of Wednesday 1st

For the upcoming trading day on Wednesday, 1st we expect RenovoRx, Inc. to open at $1.23, and during the day (based on 14 day Average True Range), to move between $1.09 and $1.33, which gives a possible trading interval of +/-$0.122 (+/-10.11%) up or down from last closing price. If RenovoRx, Inc. takes out the full calculated possible swing range there will be an estimated 20.22% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $1.18 (2.48%) than the resistance at $1.32 (9.09%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is RenovoRx, Inc. stock A Buy?

RenovoRx, Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -3.041 Sell Candidate Unchanged

Predicted Opening Price for RenovoRx, Inc. of Wednesday, May 1, 2024

Fair opening price May 1, 2024 Current price
$1.23 ( 1.93%) $1.21

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for RNXT

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 1.30 7.71 %
R2 1.28 5.50 %
R1 1.26 4.14 %
Current price: 1.21
Support S1 1.21 -0.282 %
S2 1.19 -1.65 %
S3 1.16 -3.86 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 1.50 23.97 %
R2 1.37 12.94 %
R1 1.32 9.09 %
Current price 1.21
Support S1 1.18 -2.48%
S2 1.17 -3.31%
S3 1.15 -4.96%

FAQ

What is the symbol for RenovoRx, Inc. Stock and on which exchange is it traded?
The symbol for RenovoRx, Inc. is RNXT and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell RenovoRx, Inc. Stock?
RenovoRx, Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

How to buy RenovoRx, Inc. Stock?
RenovoRx, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy RenovoRx, Inc. Stock.

What's the current price of RenovoRx, Inc. Stock?
As of the end of day on the Apr 30, 2024, the price of an RenovoRx, Inc. (RNXT) share was $1.21.

What is the 52-week high and low for RenovoRx, Inc. Stock?
The 52-week high for RenovoRx, Inc. Stock is $3.29 and the 52-week low is $0.549.

What is the market capitalization of RenovoRx, Inc. Stock?
As of the Apr 30, 2024, the market capitalization of RenovoRx, Inc. is 20.408M.

When is the next earnings date for RenovoRx, Inc.?
The upcoming earnings date for RenovoRx, Inc. is Aug 15, 2024.
Click to get the best stock tips daily for free!

About RenovoRx, Inc.

RenovoRx. RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.... RNXT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT